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PURPOSE: To compare the effects of three methods of
values clarification (VCM): balance sheet; rating and
ranking; and a discrete choice experiment (DCE) on
decision-making about colorectal cancer (CRC) screen-
ing among adults in the US and Australia.
METHODS: Using online panels managed by a survey
research organization in the US and Australia, we
recruited adults ages 50–75 at average risk for CRC
for an online survey. Those eligible were randomized to
one of the three VCM tasks. CRC screening options
were described in terms of five key attributes: reduction
in risk of CRC incidence and mortality; nature of the
screening test; screening frequency; complications from
screening; and chance of requiring a colonoscopy (as
initial or follow-up testing). Main outcomes included
self-reported most important attribute and unlabeled
screening test preference by VCM and by country,
assessed after the VCM.
RESULTS: A total of 920 participantswere enrolled; 51%
were Australian; mean age was 59.0; 87.0 % were white;
34.2%had a 4-year college degree; 42.8%had household
incomes less than $45,000 USD per year; 44.9 % were up
to date with CRC screening. Most important attribute
differed across VCMgroups: the rating and ranking group
was more likely to choose risk reduction as most impor-
tant attribute (69.8 %) than the balance sheet group
(54.7 %) or DCE (49.3 %), p<0.0001; most important
attribute did not vary by country (p=0.236). The fecal
occult blood test (FOBT)-like test was the most frequently
preferred test overall (55.9 %). Unlabeled test choice did
not differ meaningfully by VCM. Australians were more
likely to prefer the FOBT (AU 66.2 % vs. US 45.1 %, OR
2.4, 95 % CI 1.8, 3.1). Few participants favored no
screening (US: 9.2 %, AU: 6.2 %).
CONCLUSIONS: Screening test attribute importance
varied by VCM, but not by country. FOBT was more
commonly preferred by Australians than by Ameri-
cans, but test preferences were heterogeneous in both
countries.
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decision support.
J Gen Intern Med 29(3):507–13
DOI: 10.1007/s11606-013-2701-0
© Society of General Internal Medicine 2013
INTRODUCTION
Colorectal cancer (CRC) is one of the most important
causes of cancer incidence and death worldwide, particu-
larly for developed countries such as the US and Australia.1
In 2010, CRC was the second leading cause of cancer
incidence and third leading cause of cancer deaths in
Australian adults.2 In 2012, CRC is estimated to be the
third leading cause of cancer incidence and deaths for US
adults.3 CRC screening can reduce CRC incidence and
mortality.4 Several different methods of screening are
available but no single method has been shown to be
clearly superior to others. Available options [fecal occult
blood testing (FOBT), sigmoidoscopy, colonoscopy, radio-
logic screening] differ in several important regards, making
CRC screening a good area for decision support.5–7
Decision support interventions, including decision aids
(DAs), can help patients make a decision where multiple
reasonable options exist. Consensus recommendations
suggest DAs should include some values clarification
method (VCM).8 VCMs are “methods to help patients
think about the desirability of options or attributes of
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options within a specific decision context, in order to identify
which option he/she prefers.”9 Several different VCMs are
available for health choices, including cancer screening.10
Potential options include implicit techniques (e.g., balance
sheet), in which patients receive information about the relevant
characteristics of a decision and are able to consider their
potential value on their own, and explicit techniques (e.g.,
rating, ranking, discrete choice methods including conjoint
analysis) in which patients are asked specifically to compare the
relative importance of relevant characteristics of a decision. It is
not clear whether these different VCMs may affect patient
reported values and preferences. If different VCMs produce
similar results, using shorter, simpler VCMs (e.g., ranking and
rating) should be sufficient for research and practice; if, however,
they give divergent results, research is needed to understand
which VCM leads to better clinical and decision-making
outcomes. We have previously shown that two VCMs, the
discrete choice experiment (DCE) and rating and ranking,
produce somewhat different patterns of attribute importance, but
no difference in preferred testing modality, in a small sample of
US adults considering CRC screening.11 Additionally, some
previous research outside of the health-care setting has shown
that different VCMs yield different attribute importances.12
Most developed countries recommend and have imple-
mented CRC screening, either through organized programs
or on an ad hoc basis, with variable decisions about which
test or tests to offer.13 Ideally, the type of program
implemented in a given country should reflect the majority
of its citizens’ values, including screening versus no
screening as well as the different screening options and
their attributes. Some studies have found considerable
variation in how people value different attributes, but have
not assessed variation across different countries.11,14,15
By studying the US and Australia, we were able to examine
how values and preferences for screening differ in two
countries with similar wealth but with differences in how
CRC screening has been implemented. US guidelines recom-
mend several options for screening, but implementation has
been ad hoc.6,16 Australia recommends FOBT-based screening
and has partially implemented an organized screening
program.17,18 Our primary objective in this study was to
compare three VCMs: a balance sheet of test characteristics, a
rating and ranking exercise, and a DCE, about CRC screening;
and, second, to examine how the values of: (1) US and
Australian adults and (2) previously screened and not
previously screened respondents may differ.
METHODS
Overview
We performed a randomized trial among members of an
online survey panel in the US and Australia to examine
CRC and prostate cancer screening decisions. This article
reports on the CRC screening component; we have
previously reported the findings of the prostate cancer
screening component.19 Participants completed a baseline
questionnaire, reviewed information about the screening
decision, completed their assigned VCM, and then com-
pleted a post-VCM questionnaire that assessed most
important attribute and preferred screening test choice.
Selection of Attributes and Levels
CRC screening options were described in terms of five key
attributes: reduction in risk of CRC incidence and mortality;
nature of the test (including time required, whether the test
was performed at home or at a facility, and whether it was
invasive; tend to be highly correlated); screening frequency;
complications from screening; and chance of requiring a
colonoscopy (as initial or follow-up testing). The attributes
and levels of the attributes included were based upon the
existing literature, including simulations20 and our own
previous work.11 We represented the effectiveness of CRC
screening tests over time rather than in one single
application. CRC screening tests have similar long-term
risk reduction; thus, we described all tests as having the
same level of risk reduction.7 (Table 1)
Balance Sheet Task
The balance sheet used the key attributes and levels
described above. The four commonly available testing
options (FOBT, sigmoidoscopy, colonoscopy, and radiolog-
ic testing) were described using the attributes and levels
described above, and participants were instructed to select
their preferred screening test or no testing (Appendix
Figure 1, available online).
Rating and Ranking Task
The rating and ranking task asked participants to rate (on a
scale of 0 = not important at all to 5 = very important) and
then rank the three most important screening test attributes
from the same set of key attributes described above
(Appendix Figure 2, available online).
Discrete Choice Experiment
The DCE method is based on the concept that goods and
services, including health services, can be described in terms
of a number of separate attributes and that an individual’s
valuation of the good or service depends on the combination
of those attributes. In DCE, respondents are asked to complete
a series of choice tasks. In each task, they choose between
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hypothetical alternatives, each defined by a set of attributes
and levels within these attributes. The levels of each attribute
are varied systematically in a series of questions. Respondents
choose the option that they prefer for each choice task/
question. We used NGENE (www.choice-metrics.com) to
generate a statistically efficient DCE design that minimized
sample size.21,22Our design required all participants in the
DCE group to complete a set of 16 choice scenarios, each of
which included a “no testing” option (Appendix Figure 3,
available online).
Pretesting
All instruments were pre-tested as described elsewhere.19
Participant Eligibility and Recruitment
Participants were members of an online panel maintained
by Survey Sampling International (SSI). We aimed to
recruit 900 adults with an even representation by gender
(450 men and 450 women) and country (450 US, 450
Australia). Participants were average risk (no personal or
family history of CRC) and between the ages of 50 and 75.
Prior testing history was assessed but not used to determine
eligibility. Those with visual limitations or inability to
understand English were excluded.
Study Flow
The entire study was performed online. After eligibility was
determined and consent obtained, participants received
basic information about CRC and CRC screening (Appen-
dix Figure 4, available online), completed basic demo-
graphic questions, and were randomized by SSI on a 1:1:1
basis, stratified by country, to: (1) an implicit VCM (a
balance sheet of key test attributes); (2) a rating and ranking
task; or (3) a DCE. Within each VCM group, participants
were randomized to five different attribute orders to account
for potential ordering bias. Upon task completion, partici-
pants completed a questionnaire.
Study Outcomes
Our main outcome of interest was the participant’s self-
reported most important attribute. We chose this outcome
to determine whether the VCM itself influenced how
individual participants valued key features of the decision.
We assessed this outcome after the VCM by asking each
participant to indicate “which ONE feature of colon cancer
screening is most important to you?” with responses chosen
from a list of attributes including: (1) reduction in risk of
CRC incidence and mortality, (2) the nature of the test, (3)
screening frequency, (4) complications from screening, and
(5) chance of requiring a colonoscopy (as initial or follow-
up testing).
Key secondary outcomes included unlabeled test
preference, based on a question assessed after the VCM
that included four unlabeled options (designed to repre-
sent FOBT, sigmoidoscopy, colonoscopy, and radiologic
testing), described in terms of the appropriate levels of
key attributes listed above, plus the option of not being
screened (Appendix Figure 5, available online). Respon-
dents also completed the values clarity subscale of the
Decisional Conflict Scale (DCS), which ranges from 0 to
100, with lower scores suggesting better clarity, and a
single question about intention to be screened for colon
cancer, based on a Likert scale (from strongly disagree to
strongly agree, with agree and strongly agree considered
as positive intent).23
Table 1. Attributes and Levels
Attribute Screening levels No screening levels
Nature of the test No preparation time, requires taking a stool sample,
no discomfort, no preparation time
No preparation time, no discomfort,
no recovery time
Half day preparation time, invasive test in a medical
facility, mild-moderate discomfort, 1 h recovery time
Full day preparation time, invasive test in a medical facility,
mild-moderate discomfort, 24 h preparation time
Frequency of testing Every year Never
Every 5 years
Every 10 years
Chance of complications from
screening over 10 years
6 in 1,000 0 in 1,000
8 in 1,000
10 in 1,000
Chance of needing a colonoscopy
as a result of screening over 10 years
45 % 0 %
60 %
100 %
Ability to reduce mortality from CRC Your risk of getting colon cancer is reduced from about
6 % to 3 % and your risk of dying from colon cancer
is reduced from about 3 % to 1.5 %
Your risk of getting colon remains about
6 % and your risk of dying from colon
cancer remains about 3 %
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ANALYSES
Main Analyses
We performed initial descriptive analyses with means and
proportions, pooled across VCM groups. We then used chi-
squared, ANOVA, and logistic regression for bivariate
analyses first across the three VCM task groups and then
between US and Australian participants and between
participants who had and had not previously completed
any CRC screening test (previous screening status).
Because there were some baseline differences across
country and previous screening groups, we performed
multivariate analyses using logistic or linear regression,
adjusted for age, race, education, and income.
Ethical Considerations
This study was approved by the University of North
Carolina Institutional Review Board on April 28, 2011




We screened 3,076 individuals from October 12–27, 2011.
Of these, 2,010 were ineligible or declined participation,
and 1,066 were randomized. Of these 1,066 individuals,
920 (86.3 %) completed the full survey.
Baseline Characteristics
The mean age was 59 (range 50–72), 49.9 % were female,
and 87 % were white. There were no important demo-
graphic differences across the VCM task groups. We
observed several differences in baseline characteristics
between US and Australian participants: Australian respon-
dents were more likely to be white (p<0.0001), less well-
educated (p<0.0001), and less likely to be up to date with
screening (p<0.0001) (Table 2). Those who had not
previously completed any CRC screening test were slightly
younger than those who had previously completed a
screening test (57.7 vs. 59.8 years, p<0.0001).
Main Outcomes
Most Important Attribute. The majority of respondents
across all VCM groups (57.9 %) chose risk reduction as
most important attribute.
By VCM. The individual-level choice of most important
attribute differed by VCM. We found that those who
received the rating and ranking exercise were the most
likely to choose risk reduction over any other attribute
(OR=1.92; 95 % CI 1.38, 2.67) (Table 3).
By Country. Most important attribute did not differ by
country in adjusted or unadjusted analyses (Table 3).
By Previous Screening History. After adjusting for VCM
task, country, and demographic characteristics, we found
Table 2. Participant Characteristics by Task Group and by Country
Overall Balance sheet Rating and ranking DCE US AUS
n=920 n=309 n=305 n=306 n=452 n=468
Mean age (SD) 59 (5.6) 58.93 (5.8) 58.94 (5.6) 59.14 (5.6) 58.8 (5.8) 59.2 (5.5)
% % % % % %
Female 49.9 47.6 49.5 52.6 50 49.8
Country
USA 49.1 48.5 49.5 49.4 – –
Australia 50.9 51.5 50.5 50.6 – –
Race/ethnicity
White 86.9 87.7 86.9 86.3 79.9 93.8
Non-white 120 12.3 13.1 13.7 20.1 6.2
Education
<HS 6.5 5.8 7.2 8.6 1.8 11.1
HS grad/some college 59.2 61.8 54.8 61.1 53.5 64.7
College grad or more 34.2 32.4 38.0 32.3 44.7 24.2
Income
<$30,000 24.9 24.9 24.9 24.8 25.4 24.4
$30,000–59,999 32.1 33.3 31.8 31.1 32.5 31.6
>$60,000 34.5 33.7 35.7 34.0 36.3 32.7
Prefer not to answer 8.6 8.1 7.6 10.1 5.8 11.3
CRC testing
Up to date 44.9 49.2 42.3 43.14 54.0 36.1
Previously screened, not up to date 16.3 12.6 18.7 17.65 11.5 20.9
Never screened 37.2 37.2 37.4 36.9 33.4 40.8
Don’t know 1.6 1.0 1.6 2.3 1.1 2.2
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that those who had not completed screening in the past,
compared to those who had, were much less likely to
choose risk reduction as most important attribute over any
other attribute (OR=0.45; 95 % CI 0.34, 0.61).
Unlabeled Test Preference. The majority of respondents in
all VCM groups chose the FOBT-like test (55.9 %), and the
fewest chose the radiologic-like test (7.4 %). Additionally,
very few respondents chose the “no testing” option (8.1 %)
(Table 4).
By VCM. No meaningful differences in test preference
emerged based on VCM task (Table 4).
By Country. Australians were more likely than US
respondents to choose the FOBT-like test among the
unlabeled testing options (AU: 66.3 % vs. US: 45.1 %)
(Table 4). This relationship did not change after controlling
for task, previous screening status, and demographic
characteristics.
By Previous Screening Group. No meaningful differences
emerged based on whether or not the individual had
previously completed any CRC screening test. However,
among the previously screened, those who had previously
completed an FOBT, compared with any other screening
test, were much more likely to choose the FOBT-like test
(OR 2.2, 95 % CI 1.49, 3.25), controlling for task and
demographic characteristics.
Values Clarity
Mean post-task values clarity score was 20.45, suggesting
generally clear values. This result did not differ meaning-
fully across VCM group or country.
By Previous Screening Group. In bivariate analysis, the
mean values clarity score for those who had not previously
completed screening was significantly higher (lower clarity of
values) than for those who had previously completed screening
(not previously screened: 24.2; previously screened: 18.1; p<
0.0001). This relationship did not change after controlling for
task, country, and demographic characteristics.
Intent to be Screened
Most respondents across all VCM task groups reported that
they intended to be screened (70 %), and this result did not
differ across VCM groups or countries.
By Previous Screening Group. Those who had never been
previously screened, compared to those who had, were
much less likely to intend to be screened in the future.
Nearly half (49.6 %) of those who had not previously
completed screening did not intend to complete screening in
the future compared to 17.6 % of those who had
(p<0.0001). The relationship did not change after
controlling for task, country, and demographic
characteristics (OR 0.19, 95 % CI 0.14, 0.27; p<0.0001).
Table 4. Unlabeled Test Preference by Task Group and by Country
Overall Balance sheet Rating and ranking DCE US Australia
n=920 n=309 n=305 n=306 n=452 n=439
Test % % % % % %
FOBT 55.9 54.7 57.5 55.23 45.1 66.3
SIG 16.9 15.5 16.4 18.6 18.4 15.4
COLO 14.3 13.4 8.5 11.7 16.8 6.8
RAD 7.4 8.9 7.2 7.8 10.4 5.3
No testing 7.7 8.1 3.6 11.4 9.3 6.2
Table 3. Most Important Attribute by Task Group and by Country
Overall Balance sheet Rating and ranking DCE US Australia
n=920 n=309 n=305 n=306 n=452 N=468
Attribute % % % % % %
Nature of the test 18.5 20.1 14.8 20.6 19.0 18.0
Frequency of the test 12.7 12.9 8.5 16.7 11.3 14.1
Chance of complications 6.5 5.8 3.9 9.8 7.5 5.6
Chance of needing a colonoscopy over 10 years 4.4 6.5 3.0 3.6 6.2 2.6
Reduction in risk of getting or dying from colon cancer 57.9 54.7 69.8 49.3 56.0 59.8
511Brenner et al.: Values Clarification for Colorectal Cancer ScreeningJGIM
DISCUSSION
To our knowledge, this is the first large, multicountry,
randomized trial comparing different VCMs related to CRC
screening. We found that different VCMs produced differ-
ent results in terms of an individual’s most important CRC
screening test attribute but did not affect unlabeled test
preference, post-task values clarity, or intent to be screened.
Australians were more likely to select the FOBT-like test
among unlabeled test options than US participants, perhaps
reflecting this test’s higher profile in Australia. Intent to be
screened was high in both countries, suggesting that
informed participants generally favor screening. Comparing
people who had and had not previously completed CRC
screening revealed differences in most important attribute,
post-task values clarity, and intention to complete screening
in the future.
These findings suggest that the VCM affects how
respondents report what attributes of CRC screening they
value most. Previous research has shown that how patients
value features or attributes of CRC screening varies widely,
but few, if any, studies have considered the effect of specific
VCM.11,14 In this study, slightly more than half of
respondents selected risk reduction as most important.
Those who did not may have perceived the risk of CRC
and the reduction in risk as being very small and thus did
not consider this attribute to be “important.” Those who
completed the rating and ranking task were the most likely
to select risk reduction as most important over any other
attribute. This is consistent with previous studies that
included a rating and ranking task for CRC and other
cancer screening decisions.11,19,24 This relationship may
suggest that VCM influences how respondents balance
attributes of CRC screening. Additionally, rating and
ranking tasks may not promote as much deliberation about
the attributes and their relationships with each other,
potentially promoting selection of the most accessible
attribute, risk reduction, as most important.25 Regardless,
if the method of assessing values affects reported values, as
our results suggest, it becomes important to understand
what such differences mean, perhaps through qualitative
methods.
Interestingly, despite differences in self-reported most
important attribute by VCM, unlabeled test preference did
not differ by VCM. This may have been influenced by the
portrayal of risk reduction as the same across all screening
modalities. We did find that Australians were much more
likely to prefer the FOBT-like test than Americans. This
may suggest that the emphasis on FOBT in the Australian
screening program is reflective of the values of Australians.
Alternatively, it could reflect Australians increased famil-
iarity with FOBT, as it is the only recommended screening
test in Australian guidelines and in the Australian national
screening program.26,27 Finally, we saw previous experi-
ence with screening affected attitudes about screening.
Those who had not previously been screened were much
less likely to select reduction in risk of mortality as most
important and were less likely to intend to be screened in
the future compared to those who had been screened
previously. This may suggest an underlying difference in
understanding of mortality risk from CRC in people who
have not previously completed screening, but additional
research would be necessary to further understand this
relationship.
Our study adds to the limited body of research examining
the effects of explicit values clarification methods versus no
values clarification, implicit methods, or other explicit
methods, on decisions about CRC screening or other health
conditions. Other current research has shown inconsistent
effects of values clarification, and little research has
compared the effects of different values clarification
methods.11 Because there are several effective options for
CRC screening that differ in risks and benefits, it is
important that an individual’s values are represented when
a decision is made. We observed a similar result for prostate
cancer screening decisions, finding that different values
clarification methods produce different patterns of attribute
importance and different preferences for screening when
presented with an unlabeled choice.19 This study represents
an early attempt to understand how different values
clarification methods could be used to help patients make
a values-concordant decision.
Although useful, this study has several limitations. First,
the study sample was relatively highly educated and
primarily White, and our findings may not be generalizable
outside of these populations. Second, we chose not to
include out-of-pocket cost as an attribute of CRC screening.
Given our goal to compare across countries, we could not
make the attributes or levels country-specific. The cost
structure for CRC tests differs between the US and
Australia, and we could not resolve this difference. Third,
while we were able to detect differences in selection of most
important attribute across VCM, we cannot draw any
conclusions on which method produces the most accurate
choice. Finally, this study was hypothetical and did not
follow respondents forward in time to look at actual
screening choices.
In conclusion, we found that different VCMs produced
different results in terms of most important attribute, but not
in terms of unlabeled test preference, values clarity, or
intention to be screened. Unlabeled test preference differed
across countries, and attitudes about screening differed
according to past experience with testing. Future research
should include a qualitative component to begin to
understand perceptions of the results of different VCM
tasks, including which results are most accurate. Studies
should also include longitudinal follow-up to determine
whether different VCMs produce differences in actual
completion of CRC screening, test choice, and long-term
outcomes. Finally, future research should explore differ-
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ences in values between actively (specifically chosen not to
be screened) and passively unscreened people.
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